AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to address concerns over its business in China than on its earnings report alone.

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price target of p13,100.00. The company’s shares opened ...

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...

Select listed pharmaceuticals companies including Pfizer Ltd, Novartis India Ltd, AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A variety of stories feature on Saturday's front pages. The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

At AstraZeneca, we approach this by working in partnership across all our stakeholder groups, on a transparent basis with open dialogue. We also need to address inequalities in access to ...